Breaking News
Get 50% Off 0
💎 Bargain Hunter: Undervalued stocks with massive upside potential
Get the list
Close

Imugene Ltd (IMU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.263 -0.013    -4.55%
06:59:53 - Closed. Currency in AUD
Type:  Equity
Market:  Australia
ISIN:  AU000000IMU9 
  • Volume: 1,406,889
  • Bid/Ask: 0.260 / 0.265
  • Day's Range: 0.260 - 0.275
Imugene Ltd 0.263 -0.013 -4.55%

Imugene Ltd Company Profile

 
Get an in-depth profile of Imugene Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

5

Equity Type

ORD

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Contact Information

Address 4-6 Bligh Street Suite 12.01, Level 12
Sydney, 2000
Australia
Phone 61 2 9423 0881
Fax 61 2 9423 0881

Top Executives

Name Age Since Title
Paul Edward-Alexander Hopper 67 2012 Executive Chairman
Leslie Chong - 2015 CEO, MD & Executive Director
Yelena Y. Janjigian - 2016 Scientific Advisory Board Member
Lesley Russell 63 2019 Independent Non-Executive Director
Yuman Fong - 2019 Chair of Oncolytic Virotherapy Scientific Advisory Board
Tanios Bekaii-Saab - 2018 Member of Scientific Advisory Board
Prasad S. Adusumilli - 2019 Member of Scientific Advisory Board
Rebecca Auer - 2019 Member of Scientific Advisory Board
Neil H. Segal - 2014 Member of Scientific Advisory Board
Kimberlee Cobleigh Drapkin 56 2023 Non-Executive Director
Peter Schmid - 2017 Member of Scientific Advisory Board
Josep Tabernero Caturla - 2018 Member of Scientific Advisory Board
Pravin T. P. Kaumaya - 2018 Member of Scientific Advisory Board
Jakob Dupont 59 2022 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMU Comments

Write your thoughts about Imugene Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email